Area privada5

Our team will begin the evaluation of a novel drug that is administered intrathecally. It is a phase I trial with an oligonucleotide, administered intrathecally, which aims to reduce the formation of alfasinuclein, by inhibiting the LRKK2 gene.

Compartir:
CategoryParkinson

No dude en llamarnos 1-+34 935 656 000